Braveheart Bio, Inc.

Braveheart Bio, Inc. (BRVE) priced its initial public offering on Aug 6, 2026 at $18.00 per share, raising $382.5M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $1.32B. Goodwin Procter advised the company and Covington & Burling advised the underwriters.

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy and other cardiovascular diseases. Its lead candidate, BHB-1893, is an oral cardiac myosin inhibitor for obstructive and non-obstructive HCM.

Status

IPO

Ticker

BRVE

Exchange

Nasdaq Global Market

Priced

Aug 6, 2026

IPO price

$18.00

Raised

$382.5M

Market cap at IPO price

$1.32B

First filed

Jul 15, 2026

Company counsel

Goodwin Procter

Underwriters' counsel

Covington & Burling

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.